Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ace J Hatch

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Scientific Reports|November 7, 2018
Genetic variation determines VEGF-A plasma levels in cancer patientsFederico Innocenti, Chen Jiang, Alexander B Sibley, et al.
The Oncologist|March 25, 2018
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced CancerGordana Vlahovic, Kellen L Meadows, Ace J Hatch, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Scientific Reports|November 7, 2018
Genetic variation determines VEGF-A plasma levels in cancer patientsFederico Innocenti, Chen Jiang, Alexander B Sibley, et al.
The Oncologist|March 25, 2018
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced CancerGordana Vlahovic, Kellen L Meadows, Ace J Hatch, et al.
Molecular Cancer Therapeutics|August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Pageof 2